CareDx Partners with the National Kidney Foundation to Advocate for Kidney Transplant Patients

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is teaming up with the National Kidney Foundation (NKF) to support National Kidney Month initiatives aimed at improving outcomes for kidney transplant recipients and those suffering from kidney failure.

This marks the seventh consecutive year that CareDx is supporting NKF’s Kidney Patient Summit on Capitol Hill, which is taking place virtually this year on March 2, 2022. Patient representatives will be advocating for more research funding to accelerate the early detection of chronic kidney disease, which could help physicians reverse or delay the need for transplantation.

“CareDx is completely committed to raising awareness, amplifying, and supporting the incredible work being done by the National Kidney Foundation to improve outcomes for patients living with chronic kidney disease and those undergoing transplantation,” said Reg Seeto, CEO and President of CareDx. “From legislative advocacy to patient education, these efforts represent our sacrosanct commitment to help patients with kidney disease at every stage of their journey – from early interventions to pre-transplant care to post-transplant monitoring.”

“Care Dx has been a steadfast supporter and advocate for people with kidney disease, especially through their advocacy around the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act, which became law in 2020,” said Kevin Longino, Chief Executive Officer at the National Kidney Foundation. “We are grateful for their partnership and look forward to working with them to enact the Living Donor Protection Act, to increase federal funding for kidney research and prevention activities, and to advance other kidney policy priorities.”

CareDx is also co-hosting an educational webinar with the Northern California Chapter of NKF to help patients gain new insights on:

• Innovations in Kidney Care. Held on March 15, this webinar will cover the latest advances in wearable dialysis, post-organ transplant surveillance, and digital apps to help patients achieve their health goals. Webinar speakers include the following: Glenda V. Roberts, a kidney transplant recipient and the Director of External Relations and Patient Engagement at the Kidney Research Institute Center for Dialysis Innovation, Department of Medicine, Division of Nephrology, University of Washington; Jay A. Graham MD, MBA, FACS, Associate Professor, Abdominal Transplant Surgeon, Pancreas Transplantation Surgical Director, Montefiore-Einstein Center for Transplantation; and Jeff Rogers, MD, FACS, Clinical Field Director at CareDx and former Abdominal Transplant Surgeon. The webinar will be moderated by Alexandra Harrison-Flaxman, a kidney transplant recipient and Community Engagement Manager at CareDx. To register for the webinar, sign up here.
  

March is National Kidney Month, a time when communities across the country raise awareness about kidney disease. According to the National Institutes of Health (NIH), chronic kidney disease (CKD) is a serious condition affecting 1 in 7 adults and an estimated 37 million people in the United States.¹ Despite its prevalence, early-stage kidney disease usually has no symptoms.¹ Often overlooked until symptoms appear, CKD is progressive and can put patients at risk for serious health complications, including kidney failure.¹

About CareDx – The Transplant Company
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s partnership with NKF to support National Kidney Month initiatives (the “Partnership”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of the partnership; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com

Investor Relations
Ian Cooney
(415) 722-4563
investor@CareDx.com

Reference:

1. National Institute of Health Kidney Disease Statistics for the United States. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Accessed online February 24, 2022.